Glucose metabolism after pancreas transplantation: Cyclosporine versus tacrolimus

Transplantation

Volumn 77, Issue 10, 2004, Pages 1561-1565

  Dieterle, Christoph D ^a,b   Schmauss, Susanne ^a   Vietenhansl, Martin ^a   Gutt, Bodo ^a   Illner, Wolf Dieter ^b   Land, Walter ^b   Landgraf, Rüdiger ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; TACROLIMUS;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GRAFT SURVIVAL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS SECRETION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; SURVIVAL RATE;

ADULT; BLOOD GLUCOSE; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; POSTOPERATIVE PERIOD; TACROLIMUS; TIME FACTORS;

EID: 2542522272     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000129063.65446.65     Document Type: Article

References (27)

1. Kaufman DB, Leventhal JR, Stuart J, et al. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. Transplant Proc 1999; 31: 615.
2. Jordan ML, Shapiro R, Gritsch HA, et al. Long-term results of pancreas transplantation under tacrolimus immunosuppression. Transplantation 1999; 67: 266.
3. Merion RM, Henry ML, Melzer JS, et al. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allegraft rejection after simultaneous pancreas-kidney transplantation. Transplantation 2000; 15: 105.
4. Jordan ML, Chakrabarti P, Luke P, et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation 2000; 9: 65.
5. Reddy KS, Stratta RJ, Shokouh-Amiri H, et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation 2000; 69: 49.
6. Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: Analysis of incidence and risk factors. Transplantation 2001; 72: 1655.
7. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes. Diabetes Care 2002; 25: 583.
8. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
9. Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15: 89.
10. Bending JJ, Ogg CS, Viberti GC. Diabetogenic effect of cyclosporin. Br Med J (Clin Res Ed) 1987; 29: 401.
11. Scantlebury V, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169.
12. Paolillo JA, Boyle GJ, Law YM, et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immuno-suppression. Transplantation 2001; 71: 252.
13. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation: FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
14. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834.
15. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of FK506-based inununosuppression after renal transplantation. Transplantation 1995; 59: 485.
16. Stratta RJ. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: A multi-center report. The FK/MMF Multi-Center Study Group. Transplant Proc 1997; 29: 654.
17. Gruessner RW. Tacrolimus in pancreas transplantation: A multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Clin Transplant 1997; 11: 299.
18. Strumph P, Kirsch D, Gooding W, et al. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. Transplantation 1995; 60: 147.
19. Tamura K, Fujimura T, Tsutsumi T, et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. Transplant Proc 1995; 27: 357.
20. Tamura K, Fujimura T, Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995; 59: 1606.
21. Redmon JB, Olson LK, Armstrong MB, et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98: 2786.
22. Shapiro R, Scantlebury VP, Jordan ML, et al. Tacrolimus in pediatric renal transplantation. Transplantation 1996; 62: 1752.
23. Filler G, Neuschulz I, Vollmer I, et al. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000; 15: 867.
24. Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46: 182.
25. First MR, Gerber DA, Hariharan S, et al. Posttransplant diabetes mellitus in kidney allograft recipients: Incidence, risk factors, and management. Transplantation 2002; 73: 379.
26. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67: 411.
27. Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients: FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875.